



May 25, 2023

**The Manager - Listing**  
**National Stock Exchange of India Limited,**  
Compliance Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai - 400051,  
Maharashtra, India

**The Manager - Listing**  
**BSE Limited,**  
Compliance Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001,  
Maharashtra, India

Dear Sir/Madam,

**Subject : Audited Financial Results of HealthCare Global Enterprises Limited (“the Company”)**

**Stock Code : BSE – 539787, NSE – HCG**

**Reference : Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”)**

Further to our intimation dated May 12, 2023, we wish to inform you that, the Board of Directors of the Company (“Board”), at their meeting held on this day, May 25, 2023, *inter alia*, has considered and approved the following agenda:

1. Audited Financial Results (Standalone and Consolidated) of the Company for the year ended March 31, 2023 together with Auditor’s Report thereon;
2. Issue and allotment of 41,250 (Forty-One Thousand Two Hundred Fifty) equity shares of the Company of INR 10 each, upon exercise of Employee Stock Options in accordance with the existing Employee Stock Option Schemes of the Company.
3. Appointment of Mr. Rajiv Maliwal (DIN: 00869035), as an Independent Director (Additional Director in terms of Section 161 of the Companies Act, 2013) of the Company for a term of three (3) years with effect from May 25, 2023, subject to the approval of shareholders of the Company, and that Mr. Maliwal shall not be liable to retire by rotation. The Company shall make detailed disclosure under Regulation 30 of SEBI LODR Regulations, 2015 in this regard.

Pursuant to Regulation 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2023, together with Auditor’s Report, as approved by the Board. The financial results are also being made available on the Company's website at [www.hcgoncology.com](http://www.hcgoncology.com)



We hereby declare that the Statutory Auditors of the Company, M/s. B S R & Co. LLP, have issued an Audit Report with an unmodified opinion on Audited Financial Results (Standalone and Consolidated) of the Company for the year ended March 31, 2023.

The Meeting of the Board of Directors commenced at 11.30 a.m. and concluded at 5.50 p.m.

Kindly take the intimation on record and acknowledge receipt of the same.

Thanking you,

For **HealthCare Global Enterprises Limited**

**Sunu Manuel**  
**Company Secretary & Compliance Officer**

**Encl: As above**

# B S R & Co. LLP

Chartered Accountants

Embassy Golf Links Business Park,  
Pebble Beach, B Block, 3rd Floor,  
No. 13/2, off Intermediate Ring Road,  
Bengaluru 560 071 India  
Tel: +91 80 4682 3000  
Fax: +91 80 4682 3999

## Independent Auditor's Report

**To the Board of Directors of HealthCare Global Enterprises Limited**

**Report on the audit of the Standalone Annual Financial Results**

### Opinion

We have audited the accompanying standalone annual financial results of HealthCare Global Enterprises Limited (hereinafter referred to as the "Company") for the year ended 31 March 2023, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive loss and other financial information for the year ended 31 March 2023.

### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results.

### Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

Registered Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

Page 1 of 3

Independent Auditor's Report (*Continued*)

**HealthCare Global Enterprises Limited**

of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

**Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results**

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.



**Independent Auditor's Report (*Continued*)**  
**HealthCare Global Enterprises Limited**

- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**Other Matter(s)**

- a. The standalone annual financial results include the results for the quarter ended 31 March 2023 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **B S R & Co. LLP**

*Chartered Accountants*

Firm's Registration No.:101248W/W-100022

  
**Vikash Gupta**

*Partner*

Bangalore

25 May 2023

Membership No.: 064597

UDIN:23064597BGYQPU4914

**HealthCare Global Enterprises Limited**

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India  
Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2023**

(Rs. in Lakhs except share data)

Sl. No.	Particulars	Quarter ended 31 March 2023 (Refer note 1)	Preceding quarter ended 31 December 2022 Unaudited	Corresponding quarter ended 31 March 2022 (Refer note 1)	Year ended 31 March 2023 Audited	Previous year ended 31 March 2022 Audited
1	<b>Income</b>					
	(a) Revenue from operations	25,819	25,217	21,967	100,557	84,983
	(b) Income from government grant	48	51	52	202	213
	(c) Other income	356	210	225	880	1,029
	<b>Total income</b>	<b>26,223</b>	<b>25,478</b>	<b>22,244</b>	<b>101,639</b>	<b>86,225</b>
2	<b>Expenses</b>					
	(a) Purchases of medical and non-medical items	6,121	6,118	5,134	24,020	21,326
	(b) Changes in inventories	219	(175)	48	(392)	(294)
	(c) Employee benefits expense	4,406	4,324	3,878	17,503	15,663
	(d) Finance costs	957	1,053	922	4,149	4,280
	(e) Depreciation and amortisation expense (refer note 2)	2,306	2,181	2,219	8,897	8,836
	(f) Medical consultancy charges	4,939	4,822	4,337	19,421	16,073
	(g) Other expenses	6,184	5,217	4,579	21,979	17,528
	<b>Total expenses</b>	<b>25,132</b>	<b>23,540</b>	<b>21,117</b>	<b>95,577</b>	<b>83,412</b>
3	<b>Profit before exceptional items and tax (1-2)</b>	<b>1,091</b>	<b>1,938</b>	<b>1,127</b>	<b>6,062</b>	<b>2,813</b>
4	<b>Exceptional items, net gain / (loss) (refer note 3)</b>	<b>(300)</b>	<b>-</b>	<b>(2,700)</b>	<b>(300)</b>	<b>5,291</b>
5	<b>Profit / (loss) before tax (3+4)</b>	<b>791</b>	<b>1,938</b>	<b>(1,573)</b>	<b>5,762</b>	<b>8,104</b>
6	<b>Tax expense</b>					
	- Current tax	90	240	(86)	700	1,570
	- Deferred tax (refer note 4)	283	282	305	1,043	2,709
	<b>Total tax expense</b>	<b>373</b>	<b>522</b>	<b>219</b>	<b>1,743</b>	<b>4,279</b>
7	<b>Profit / (loss) for the period / year (5-6)</b>	<b>418</b>	<b>1,416</b>	<b>(1,792)</b>	<b>4,019</b>	<b>3,825</b>
8	<b>Other comprehensive income / (loss)</b>					
	(i) Items that will not be reclassified subsequently to profit or loss					
	- Remeasurements of the defined benefit plans	(25)	-	(68)	(25)	(68)
	- Income tax effect on (i) above	9	-	24	9	24
	(ii) Items that will be reclassified to profit or loss					
	- Effective portion of gain on hedging instruments in a cash flow hedge	-	-	-	-	118
	- Income tax effect on (ii) above	-	-	-	-	(41)
	<b>Other comprehensive income / (loss) for the period / year, net of tax</b>	<b>(16)</b>	<b>-</b>	<b>(44)</b>	<b>(16)</b>	<b>33</b>
9	<b>Total comprehensive income / (loss) for the period / year (7+8)</b>	<b>402</b>	<b>1,416</b>	<b>(1,836)</b>	<b>4,003</b>	<b>3,858</b>
10	<b>Paid-up equity share capital (Face value of Rs. 10 each)</b>	<b>13,912</b>	<b>13,909</b>	<b>13,901</b>	<b>13,912</b>	<b>13,901</b>
11	<b>Reserves, i.e., 'Other equity'</b>				<b>100,601</b>	<b>95,868</b>
12	<b>Earnings / (Loss) per equity share (face value of Rs. 10 each)</b>	<b>Not annualised</b>	<b>Not annualised</b>	<b>Not annualised</b>	<b>Annualised</b>	<b>Annualised</b>
	(a) Basic	0.30	1.02	(1.29)	2.89	2.95
	(b) Diluted *	0.30	1.01	(1.29)	2.88	2.83
	* Since there is a loss during the corresponding quarter ended 31 March 2022, potential equity shares are not considered as dilutive and hence Diluted loss per share is same as Basic loss per share.					
	See accompanying notes to the Standalone Financial Results					



**HealthCare Global Enterprises Limited**

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2023**

<b>STANDALONE BALANCE SHEET</b>		<b>(Rs in Lakhs)</b>	
<b>Particulars</b>		<b>As at 31 March 2023 Audited</b>	<b>As at 31 March 2022 Audited</b>
<b>A</b>	<b>ASSETS</b>		
<b>I</b>	<b>Non-current assets</b>		
	(a) Property, plant and equipment	52,285	47,704
	(b) Capital work in progress	922	482
	(c) Right-of-use assets	15,346	17,627
	(d) Goodwill	9,626	9,626
	(e) Other intangible assets	1,506	2,427
	(f) Financial assets		
	(i) Investments	47,493	43,866
	(ii) Loans	-	390
	(iii) Other financial assets	2,354	2,123
	(g) Deferred tax assets (net)	-	7
	(h) Income tax assets (net)	4,366	2,995
	(i) Other non-current assets	1,821	1,499
	<b>Total non current assets</b>	<b>135,719</b>	<b>128,746</b>
<b>II</b>	<b>Current assets</b>		
	(a) Inventories	2,122	1,730
	(b) Financial assets		
	(i) Trade receivables	21,237	16,025
	(ii) Cash and cash equivalents	7,031	11,996
	(iii) Bank balance other than cash and cash equivalents above	1,006	-
	(iv) Loans	117	102
	(v) Other financial assets	2,867	4,084
	(c) Other current assets	2,873	1,679
	<b>Total current assets</b>	<b>37,253</b>	<b>35,616</b>
	<b>Total assets</b>	<b>172,972</b>	<b>164,362</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>I</b>	<b>Equity</b>		
	(a) Equity share capital	13,912	13,901
	(b) Other equity	100,601	95,868
	<b>Total equity</b>	<b>114,513</b>	<b>109,769</b>
<b>II</b>	<b>Liabilities</b>		
<b>1</b>	<b>Non-current liabilities</b>		
	(a) Financials liabilities		
	(i) Borrowings	11,272	8,203
	(ii) Lease liabilities	19,925	21,778
	(iii) Other financial liabilities	397	542
	(b) Provisions	950	779
	(c) Deferred tax liabilities (net)	1,028	-
	(d) Other non-current liabilities	2,808	1,783
	<b>Total non - current liabilities</b>	<b>36,380</b>	<b>33,085</b>
<b>2</b>	<b>Current liabilities</b>		
	(a) Financials liabilities		
	(i) Borrowings	877	2,542
	(ii) Lease liabilities	2,645	2,376
	(iii) Trade payables		
	Total outstanding dues of micro enterprises and small enterprises	263	117
	Total outstanding dues of creditors other than micro enterprises and small enterprises	10,636	9,517
	(iv) Other financial liabilities	3,499	2,981
	(b) Other current liabilities	2,535	2,563
	(c) Provisions	1,404	1,412
	(d) Current tax liabilities (net)	220	-
	<b>Total current liabilities</b>	<b>22,079</b>	<b>21,508</b>
	<b>Total equity and liabilities</b>	<b>172,972</b>	<b>164,362</b>
See accompanying notes to the Standalone Financial Results			



**HealthCare Global Enterprises Limited**

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2023**

<b>Standalone Cash Flow Statement</b>			<b>(Rs in Lakhs)</b>	
<b>Particulars</b>	<b>For the</b>		<b>For the</b>	
	<b>Year ended</b>		<b>Year ended</b>	
	<b>31 March 2023</b>		<b>31 March 2022</b>	
	<b>Audited</b>		<b>Audited</b>	
<b>Cash flows from operating activities</b>				
Profit before tax	5,762		8,104	
Adjustments for:				
Finance costs	4,149		4,279	
Gain on investment revalued at FVTPL	(4)		(12)	
Guarantee commission income	(161)		(164)	
Loss on disposal of property, plant and equipment	119		8	
Trade receivable written off (net)	3,171		-	
Provision for bad and doubtful receivables	(1,120)		978	
Expenses on employee stock option scheme	597		283	
Interest income	(634)		(758)	
Income from government grant	(202)		(213)	
Depreciation and amortisation expense	8,897		8,836	
Payables no longer required written-back	(23)		-	
Net foreign exchange (gain)	(40)		(36)	
Exceptional items (refer note 3)	300		(5,291)	
<b>Movements in working capital:</b>				
Changes in trade receivables	(5,540)		(2,218)	
Changes in inventories	(391)		(294)	
Changes in loans, financial assets and other assets	(1,784)		(1,590)	
Changes in trade payables, financial liabilities and other liabilities	1,529		1,906	
Changes in provisions	137		94	
<b>Cash generated from operations</b> (previous year amount includes settlement of Rs. 656 lakhs, pertaining to pre-existing balances pursuant to acquisition of business)	<b>14,762</b>		<b>13,912</b>	
Income taxes paid (net of refunds)	(1,725)		(1,472)	
<b>Net cash generated from operating activities (A)</b>	<b>13,037</b>		<b>12,440</b>	
<b>Cash flows from investing activities</b>				
Fixed deposits invested	(4,805)		(8,215)	
Proceeds from maturity of fixed deposits	3,780		18,906	
Acquisition of property, plant and equipment and others	(10,213)		(4,245)	
Interest received	395		1,042	
Investment in subsidiaries	(4,198)		(11,896)	
Investment - others	(20)		-	
Payment for acquisition of business (net)	-		(7,497)	
Advance for acquisition of business	(200)		-	
Proceeds from sale of investment in joint venture (net of expenses incurred towards sale of investment) [Refer note 3(d)]	-		15,721	
Proceeds from repayment of Inter-corporate deposits	-		1,020	
Proceeds from repayments of related party loans	764		-	
Proceeds from disposal of property, plant and equipment	728		29	
<b>Net cash (used) in / generated from investing activities (B)</b>	<b>(13,769)</b>		<b>4,865</b>	
<b>Cash flows from financing activities</b>				
Proceeds from issue of equity shares and warrants	89		13,216	
Proceeds from bills discounting	-		2,528	
Bills discounted settled	-		(6,516)	
Proceeds from long-term borrowings	3,889		8,558	
Repayment of long-term borrowings	(2,452)		(15,261)	
Loan foreclosure and refinancing expenses [Refer note 3(e)]	-		(503)	
Repayment of principal portion of lease liability	(2,122)		(1,784)	
Interest paid on lease liability	(2,005)		(2,516)	
Interest and other borrowing cost paid	(1,569)		(1,826)	
<b>Net cash (used) in financing activities (C)</b>	<b>(4,170)</b>		<b>(4,104)</b>	
<b>Net (decrease)/ increase in cash and cash equivalents (A+B+C)</b>	<b>(4,902)</b>		<b>13,201</b>	
Cash and cash equivalents at the beginning of the year	11,933		(1,268)	
<b>Cash and cash equivalents at the end of the year</b>	<b>7,031</b>		<b>11,933</b>	

<b>Break up of cash and cash equivalents at the end of the year</b>			<b>For the</b>	
	<b>Year ended</b>		<b>Year ended</b>	
	<b>31 March 2023</b>		<b>31 March 2022</b>	
Cash and cash equivalents at the end of the year	7,031		11,996	
Less: Bank overdrafts repayable on demand	-		(63)	
<b>Cash and cash equivalents at the end of the year</b>	<b>7,031</b>		<b>11,933</b>	





**HealthCare Global Enterprises Limited**  
**CIN : L15200KA1998PLC023489**  
 Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India  
 Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India  
**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2023**

**Notes:**

- 1 The statement of standalone financial results ('the Statement') of HealthCare Global Enterprises Limited ('the Company') for the quarter and year ended 31 March 2023 has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 25 May 2023. The Statement has been prepared in accordance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules 2015, as amended and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.

The figures for the year ended 31 March 2023 have been audited by the statutory auditor of the Company. The report of the statutory auditor is unqualified. The figures for the quarters ended 31 March 2023 and 31 March 2022 are the balancing figures between audited figures in respect of the full financial years and the published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which were subjected to limited review by the statutory auditor of the Company.

- 2 During the quarter ended 30 June 2022, the Company revised the estimated useful life for certain category of its Property, Plant and Equipment with effect from 1 April 2022 based on its technical evaluation. The effect of this revision on depreciation expense of such assets is as mentioned below:

Particulars	Rs. in lakhs		
	Quarter ended 31 March 2023	Preceding quarter ended 31 December 2022	Year ended 31 March 2023
Depreciation charge on such assets is lower and profit before tax is higher by	102	102	418

3 **Exceptional items:**

a) During the quarters and years ended 31 March 2023 and 31 March 2022, the Company performed impairment assessment for all its investments. Given the continued losses incurred and weaker forecasts, the recoverable amount of its investments in HCG EKO Oncology LLP (considering the future cash flows) was estimated to be lower than its carrying value, resulting into an impairment charge amounting to Rs. 300 Lakhs and Rs. 2,700 lakhs respectively.

b) The Company had been engaged in construction of greenfield project at leased premises in Gurugram ("project") since 2017. While the project was initially scheduled to be operational as of 2020, it was delayed due to changes in management's plan on account of operational priorities followed by the outbreak of COVID-19 pandemic. During the budgeting process in the quarter ended 31 December 2021, the Management decided to focus on increasing marketing activities and driving operational efficiencies and further invest in the upgrading and consolidating the existing footprint. As a result, the management decided not to pursue the project. The Company then had about two years of non-cancellable lease, on the said premise. Accordingly, the Company recognized impairment of capital work-in progress, right-of use assets and security deposit during the quarter ended 31 December 2021 aggregating to Rs. 4,725 Lakhs, after considering minimum lease payable and other committed costs of the project.

c) The Company invested Rs. 3,300 Lakhs in the equity shares of Suchirayu Health Care Solutions Limited (Suchirayu) on 18 November 2021 through primary funding, which resulted in increase in the Company's stake in Suchirayu from 17.7% to 78.6%, consequent to which Suchirayu became subsidiary of the Company. During the quarter ended 31 December 2021, the Company remeasured its previously held interest in Suchirayu at fair value on the date of acquisition of additional stake and recognised the resultant gain of Rs. 174 Lakhs, net as an exceptional item in accordance with the applicable Indian Accounting Standard. With the acquisition of this business, the earlier medical services and the other related arrangements were cancelled.

d) During the quarter ended 30 September 2021, the Company sold its investment in Strand Life Sciences Private Limited ('Strand') for a total consideration of Rs.15,778 lakhs, resulting in a gain of Rs.12,769 lakhs (net of expenses / other provisions). The Company also entered into Business Transfer Agreement with Strand for acquisition of the diagnostic business and the division providing clinical research site management services for a total consideration of Rs.8,080 Lakhs. With the acquisition of these businesses, the earlier outsourced Hospital Lab Management services were cancelled. The Company incurred Rs. 55 Lakhs towards legal and professional fees in respect of this acquisition during the year ended 31 March 2022.

e) During the quarter ended 30 September 2021, the Company refinanced its certain borrowings from banks and financial institutions. On account of this, the Company incurred one time expenses of Rs. 172 lakhs, net, towards foreclosure charges and accelerated amortization of loan processing fees related to earlier borrowings, which has been disclosed under Exceptional Items.


f) During the quarter and year ended 31 March 2023, the Company booked impairment of Rs. 373.50 Lakhs with respect to further investment in Niruja Product Development and Research Private Limited and HealthCare Global Senthil Multi-Specialty Hospital Private Limited. Further, the Company reversed the provision for doubtful loans aggregating Rs. 373.50 Lakhs with respect to loans given to Niruja Product Development and Research Private Limited and HealthCare Global Senthil Multi-Specialty Hospital Private Limited in the earlier years as these were repaid by the respective entities.

- 4 The Company plans to exercise the option permitted under section 115BAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019 with effect from the financial year 2023-24. Accordingly, the Company has recognised deferred taxes based on the rates applicable for the year when these deferred taxes are expected to be realized/settled. The impact of this change is recognised in the Standalone Statement of Profit and Loss over the financial year 2022-23 based on the effective tax rate. The proportionate impact of this change is as mentioned below:

Particulars	Rs. in lakhs		
	Quarter ended 31 March 2023	Preceding quarter ended 31 December 2022	Year ended 31 March 2023
Deferred tax expense is lower by and profit after taxes is higher by	90	116	404

- 5 During the year ended 31 March 2023, 310,000 equity share options (year ended 31 March 2022 : 3,305,000 equity share options) having a face value of Rs. 10 each have been granted to the eligible employees under the Employee Stock Option Scheme (ESOP Scheme) at an exercise price of Rs. 130 per share respectively. Further, 104,070 equity shares (year ended 31 March 2022 : 149,240 equity shares) are allotted during the year pursuant to exercise of equity share options.

- 6 The Company has a single operating segment of 'setting up and managing hospitals and medical diagnostic services'.



Dr. B. S. Ajaikumar  
Executive Chairman

Chicago, 25 May 2023



# B S R & Co. LLP

Chartered Accountants

Embassy Golf Links Business Park,  
Pebble Beach, B Block, 3rd Floor,  
No. 13/2, off Intermediate Ring Road,  
Bengaluru 560 071 India  
Tel: +91 80 4682 3000  
Fax: +91 80 4682 3999

## Independent Auditor's Report

### To the Board of Directors of HealthCare Global Enterprises Limited Report on the audit of the Consolidated Annual Financial Results

#### Opinion

We have audited the accompanying consolidated annual financial results of HealthCare Global Enterprises Limited (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), and its joint venture for the year ended 31 March 2023, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate/consolidated audited financial statements/financial information of the subsidiaries and a joint venture, the aforesaid consolidated annual financial results:

- include the annual financial results of the entities mentioned in Annexure I to this audit report;
- are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of consolidated net profit and other comprehensive loss and other financial information of the Group for the year ended 31 March 2023.

#### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results* section of our report. We are independent of the Group and its joint venture in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us along with the consideration of reports of the other auditor referred to in sub paragraph no. (a) of the "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion on the consolidated annual financial results.

#### Management's and Board of Directors'/Designated Partners' Responsibilities for the Consolidated Annual Financial Results

These consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements.

Registered Office

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

Page 1 of 5

VG

Independent Auditor's Report (*Continued*)**HealthCare Global Enterprises Limited**

The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the consolidated net profit/ loss and other comprehensive income and other financial information of the Group including its joint venture in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the companies/Designated Partners of limited liability partnerships (LLP) included in the Group and the respective Management and Board of Directors of its joint venture are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company/ LLP and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the respective Management and the Board of Directors of the companies/Designated Partners of LLP included in the Group and the respective Management and Board of Directors of its joint venture are responsible for assessing the ability of each company/ LLP to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors/designated partners either intends to liquidate the company/ LLP or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies/ Designated Partners of the LLP included in the Group and the respective Board of Directors of its joint venture is responsible for overseeing the financial reporting process of each company/ LLP.

**Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results**

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material



**Independent Auditor's Report (Continued)****HealthCare Global Enterprises Limited**

uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its joint venture to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial statements/financial information of the entities within the Group and its joint venture to express an opinion on the consolidated annual financial results. We are responsible for the direction, supervision and performance of the audit of financial statements/financial information of such entities included in the consolidated annual financial results of which we are the independent auditors. For the other entities included in the consolidated annual financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in sub paragraph no. (a) of the "Other Matters" paragraph in this audit report.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated annual financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

**Other Matter(s)**

- a The consolidated annual financial results include the audited financial results of nine (9) subsidiaries and step down subsidiaries, whose financial statements/ financial information reflect total assets (before consolidation adjustments) of Rs. 36,373 Lakhs as at 31 March 2023, total revenue (before consolidation adjustments) of Rs. 24,072 Lakhs and total net loss after tax (before consolidation adjustments) of Rs. 3,667 Lakhs and net cash inflows (before consolidation adjustments) of Rs 256 Lakhs for the year ended on that date, as considered in the consolidated annual financial results, which have been audited by its independent auditor. The consolidated annual financial results also include the Group's share of total net loss after tax of Rs. 2 Lakhs for the year ended 31 March 2023, as considered in the consolidated annual financial results, in respect of a joint venture, whose financial statements/financial informations have been audited by its independent auditor. The independent auditor's report on financial statements/ financial information of these entities have been furnished to us by the management.

Our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the reports of such auditors and the procedures performed by us are as stated in paragraph above.

Our opinion on the consolidated annual financial results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

Vy.

**Independent Auditor's Report (Continued)**  
**HealthCare Global Enterprises Limited**

- b. The consolidated annual financial results include the results for the quarter ended 31 March 2023 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For B S R & Co. LLP

*Chartered Accountants*

Firm's Registration No.:101248W/W-100022



**Vikash Gupta**

*Partner*

Bangalore

25 May 2023

Membership No.: 064597

UDIN:23064597BGYQPT2572

## Independent Auditor's Report (Continued)

## HealthCare Global Enterprises Limited

## Annexure I

List of entities included in consolidated annual financial results.

Sr. No	Name of component	Relationship	Country of incorporation
1	BACC Healthcare Private Limited	Subsidiary	India
2	HCG Medi-Surge Hospitals Private Limited	Subsidiary	India
3	HCG Oncology LLP	Subsidiary	India
4	HCG Oncology Hospitals LLP (formerly known as Apex HCG Oncology Hospitals LLP)	Subsidiary	India
5	HCG Manavata Oncology LLP	Subsidiary	India
6	Malnad Hospital & Institute of Oncology Private Limited	Subsidiary	India
7	HealthCare Diwan Chand Imaging LLP	Subsidiary	India
8	HCG NCHRI Oncology LLP	Subsidiary	India
9	HCG EKO Oncology LLP	Subsidiary	India
10	HCG Sun Hospitals LLP	Subsidiary	India
11	Niruja Product Development & Healthcare Research Private Limited	Subsidiary	India
12	HealthCare Global Senthil Multi Specialty Private Limited	Subsidiary	India
13	Suchirayu Health Care Solutions Limited	Subsidiary	India
14	HCG (Mauritius) Pvt. Ltd.	Subsidiary	Mauritius
15	HealthCare Global (Africa) Private Limited	Step-down subsidiary	Mauritius
16	Healthcare Global (Uganda) Private Limited	Step-down subsidiary	Uganda
17	Healthcare Global (Tanzania) Private Limited	Step-down subsidiary	Tanzania
18	Healthcare Global (Kenya) Private Limited	Step-down subsidiary	Kenya
19	Cancer Care Kenya Limited	Step-down subsidiary	Kenya
20	Advanced Molecular Imaging Limited	Joint Venture	Kenya

14.

<p align="center"> <b>HealthCare Global Enterprises Limited</b>  <b>CIN : L15200KA1998PLC023489</b>  Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India  Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India  <b>STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2023</b> </p>						
(Rs. in Lakhs except share data)						
Sl. No.	Particulars	Quarter ended 31 March 2023	Preceding quarter ended 31 December 2022	Corresponding quarter ended 31 March 2022	Year ended 31 March 2023	Previous year ended 31 March 2022
		(Refer note 1)	Unaudited	(Refer note 1)	Audited	Audited
1	<b>Income</b>					
	(a) Revenue from operations	44,098	42,391	36,389	169,141	139,478
	(b) Income from government grant	73	77	74	303	301
	(c) Other income	465	365	301	1,318	1,267
	<b>Total income</b>	<b>44,636</b>	<b>42,833</b>	<b>36,764</b>	<b>170,762</b>	<b>141,046</b>
2	<b>Expenses</b>					
	(a) Purchases of medical and non-medical items	11,587	10,885	9,103	43,238	36,097
	(b) Changes in inventories	53	(134)	(1)	(831)	(607)
	(c) Employee benefits expense	6,886	6,922	6,067	27,312	23,365
	(d) Finance costs	2,563	2,708	2,414	10,350	9,777
	(e) Depreciation and amortisation expense (refer note 2)	4,220	4,077	4,110	16,347	15,828
	(f) Medical consultancy charges	9,129	8,836	8,427	35,611	29,582
	(g) Other expenses	8,884	8,408	6,552	34,046	27,544
	<b>Total expenses</b>	<b>43,322</b>	<b>41,702</b>	<b>36,672</b>	<b>166,273</b>	<b>141,586</b>
3	<b>Profit / (loss) before share of loss of an associate / joint venture, exceptional items and tax (1-2)</b>	<b>1,314</b>	<b>1,131</b>	<b>92</b>	<b>4,489</b>	<b>(540)</b>
4	Share of (loss) of an associate / joint venture	(1)	(1)	-	(2)	(144)
5	<b>Profit / (loss) before exceptional items and tax (3+4)</b>	<b>1,313</b>	<b>1,130</b>	<b>92</b>	<b>4,487</b>	<b>(684)</b>
6	Exceptional items, net gain (refer note 3)	-	-	-	-	9,461
7	<b>Profit before tax (5+6)</b>	<b>1,313</b>	<b>1,130</b>	<b>92</b>	<b>4,487</b>	<b>8,777</b>
8	<b>Tax expense</b>					
	- Current tax	269	512	131	1,538	2,371
	- Deferred tax (refer note 4)	479	198	(264)	1,187	2,514
	<b>Total tax expense</b>	<b>748</b>	<b>710</b>	<b>(133)</b>	<b>2,725</b>	<b>4,885</b>
9	<b>Profit for the period / year (7-8)</b>	<b>565</b>	<b>420</b>	<b>225</b>	<b>1,762</b>	<b>3,892</b>
10	<b>Other comprehensive income / (loss)</b>					
	(i) Items that will not be reclassified subsequently to profit or loss					
	- Remeasurements of the defined benefit plans	(52)	-	(69)	(52)	(69)
	- Income tax effect on (i) above	10	-	19	10	19
	(ii) Items that will be reclassified to profit or loss					
	- Exchange differences on translation of financial statements of foreign operations	(199)	(31)	(54)	(90)	(178)
	- Effective portion of gain on hedging instruments in a cash flow hedge	-	-	-	-	116
	- Income tax effect on (ii) above	-	-	-	-	(41)
	<b>Other comprehensive (loss) for the period / year, net of tax</b>	<b>(241)</b>	<b>(31)</b>	<b>(104)</b>	<b>(132)</b>	<b>(153)</b>
11	<b>Total comprehensive income for the period / year (9+10)</b>	<b>324</b>	<b>389</b>	<b>121</b>	<b>1,630</b>	<b>3,739</b>
	<b>Profit / (loss) for the period / year attributable to:</b>					
	Owners of the Company	837	754	599	2,934	5,373
	Non-controlling interests	(272)	(334)	(374)	(1,172)	(1,481)
	<b>Other comprehensive income / (loss) for the period / year attributable to</b>					
	Owners of the Company	(216)	(33)	(92)	(147)	(134)
	Non-controlling interests	(25)	2	(12)	15	(19)
	<b>Total comprehensive income / (loss) for the period / year attributable to</b>					
	Owners of the Company	621	721	507	2,787	5,239
	Non-controlling interests	(297)	(332)	(386)	(1,157)	(1,500)
12	Paid-up equity share capital (Face value of Rs. 10 each)	13,912	13,909	13,901	13,912	13,901
13	Reserves, i.e., 'Other equity'				72,141	73,128
14	<b>Earnings / (Loss) per equity share (face value of Rs. 10 each)</b>	<b>Not annualised</b>	<b>Not annualised</b>	<b>Not annualised</b>	<b>Annualised</b>	<b>Annualised</b>
	(a) Basic	0.60	0.54	0.43	2.11	4.14
	(b) Diluted	0.60	0.54	0.43	2.10	3.97
	See accompanying notes to the Consolidated Financial Results					



**HealthCare Global Enterprises Limited**

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

**STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2023**

CONSOLIDATED BALANCE SHEET		(Rs in Lakhs)	
Particulars		As at 31 March 2023 Audited	As at 31 March 2022 Audited
<b>A</b>	<b>ASSETS</b>		
<b>I</b>	<b>Non-current assets</b>		
	(a) Property, plant and equipment	97,183	93,153
	(b) Capital work in progress	1,818	2,173
	(c) Right-of-use assets	38,127	40,454
	(d) Goodwill	18,123	18,127
	(e) Other intangible assets	1,867	2,980
	(f) Investment in equity accounted investee	285	301
	(g) Financial assets		
	(i) Investments	684	580
	(ii) Other financial assets	5,426	5,456
	(h) Deferred tax assets (net)	527	595
	(i) Income tax assets (net)	5,744	4,588
	(j) Other non-current assets	3,784	3,311
	<b>Total non-current assets</b>	<b>173,568</b>	<b>171,718</b>
<b>II</b>	<b>Current assets</b>		
	(a) Inventories	3,829	2,997
	(b) Financial assets		
	(i) Trade receivables	30,251	21,745
	(ii) Cash and cash equivalents	17,462	19,751
	(iii) Bank balance other than cash and cash equivalents above	2,202	-
	(iv) Loans	177	161
	(v) Other financial assets	721	3,413
	(c) Other current assets	3,392	2,168
	<b>Total current assets</b>	<b>58,034</b>	<b>50,235</b>
	<b>Total assets</b>	<b>231,602</b>	<b>221,953</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>I</b>	<b>Equity</b>		
	(a) Equity share capital	13,912	13,901
	(b) Other equity	72,141	73,128
	<b>Equity attributable to equity holders of the Company</b>	<b>86,053</b>	<b>87,029</b>
	Non-controlling interests	889	1,343
	<b>Total equity</b>	<b>86,942</b>	<b>88,372</b>
<b>II</b>	<b>Liabilities</b>		
<b>1</b>	<b>Non-current liabilities</b>		
	(a) Financials Liabilities		
	(i) Borrowings	36,174	36,287
	(ii) Lease liabilities	45,306	46,590
	(b) Provisions	1,319	1,051
	(c) Deferred tax liabilities (net)	1,237	128
	(d) Other non-current liabilities	3,593	2,550
	<b>Total non-current liabilities</b>	<b>87,629</b>	<b>86,606</b>
<b>2</b>	<b>Current liabilities</b>		
	(a) Financials liabilities		
	(i) Borrowings	3,759	4,476
	(ii) Lease liabilities	4,880	4,114
	(iii) Trade payables		
	Total outstanding dues of micro enterprises and small enterprises	489	203
	Total outstanding dues of creditors other than micro enterprises and small enterprises	24,356	19,192
	(iv) Other financial liabilities	14,038	9,359
	(b) Other current liabilities	7,551	7,850
	(c) Provisions	1,711	1,728
	(d) Current tax liabilities (net)	247	53
	<b>Total current liabilities</b>	<b>57,031</b>	<b>46,975</b>
	<b>Total equity and liabilities</b>	<b>231,602</b>	<b>221,953</b>
See accompanying notes to the Consolidated Financial Results			





**HealthCare Global Enterprises Limited**  
CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India  
Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

**STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2023**

Consolidated Cash Flow Statement		(Rs in Lakhs)	
Particulars	For the year ended 31 March 2023	For the year ended 31 March 2022	
	Audited	Audited	
<b>Cash flows from operating activities</b>			
Profit before tax	4,487	8,777	
Adjustments for:			
Finance costs	10,350	9,777	
Gain on investment revalued at FVTPL	(3)	(12)	
Loss on disposal of property, plant and equipment	132	64	
Trade receivable written off (net)	3,171	-	
Provision for bad and doubtful receivables	(1,541)	1,506	
Expenses on employee stock option scheme	651	311	
Interest income	(1,182)	(1,156)	
Gain on termination of lease	(39)	-	
Payables no longer required written back	(22)	-	
Depreciation and amortisation expense	16,347	15,828	
Income from government grant	(303)	(301)	
Net foreign exchange (gain)	(34)	(41)	
Share of loss of equity accounted investees	2	143	
Exceptional items (refer note 3)	-	(9,461)	
<b>Movements in working capital:</b>			
Changes in trade receivables	(7,855)	(4,044)	
Changes in inventories	(831)	(608)	
Changes in loans, financial assets and other assets	(1,734)	(1,999)	
Changes in trade payables, financial liabilities and other liabilities	5,635	4,430	
Changes in provisions	199	269	
<b>Cash generated from operations</b> (previous year amount includes settlement of Rs. 656 lakhs, pertaining to pre-existing balances pursuant to acquisition of business)	27,430	24,382	
Income taxes paid (net of refunds)	(2,272)	(2,370)	
<b>Net cash generated from operating activities (A)</b>	25,158	22,012	
<b>Cash flows from investing activities</b>			
Margin money deposits, net	-	(1,226)	
Fixed deposits invested	(6,321)	(8,215)	
Proceeds from maturity of fixed deposits	5,019	22,780	
Proceeds from disposal of property, plant and equipment	756	79	
Acquisition of property, plant and equipment and others	(13,323)	(7,123)	
Receipt from government grant	129	-	
Interest received	658	1,370	
Proceeds from repayment of Inter-corporate deposits	-	1,020	
Investment in associate	-	(180)	
Investment - others	(20)	-	
Payment of share application money	-	(25)	
Acquisition of businesses (net of cash and cash equivalents) [Refer notes 3(c),(e)]	-	(11,743)	
Advance for acquisition of business	(200)	-	
Proceeds from sale of investment in joint venture (net of expenses incurred towards sale of investment) [Refer note 3(c)]	-	15,721	
<b>Net cash (used) in / generated from investing activities (B)</b>	(13,302)	12,458	
<b>Cash flows from financing activities</b>			
Proceeds from issue of equity shares and warrants	89	13,216	
Payment towards settlement of dues to retiring partner	-	(242)	
Proceeds from bills discounting	-	2,528	
Bills discounted settled	-	(6,516)	
Proceeds from long-term borrowings	5,543	16,963	
Repayment of long-term borrowings	(6,276)	(28,040)	
Loan foreclosure and refinancing expenses [Refer note 3(d)]	-	(856)	
Repayment of principle portion of lease liability	(3,802)	(3,215)	
Interest paid on lease liability	(4,772)	(5,293)	
Interest and other borrowing cost paid	(4,789)	(4,033)	
<b>Net cash (used) in financing activities (C)</b>	(14,007)	(15,488)	
<b>Net (decrease)/ increase in cash and cash equivalents (A+B+C)</b>	(2,151)	18,982	
Cash and cash equivalents at the beginning of the year	19,269	287	
<b>Cash and cash equivalents at the end of the year</b>	17,118	19,269	

Break up of cash and cash equivalents at the end of the year	For the year ended 31 March 2023	For the year ended 31 March 2022
Cash and cash equivalents at the end of the year	17,462	19,751
Less: Bank overdrafts repayable on demand	(344)	(482)
<b>Cash and cash equivalents at the end of the year</b>	17,118	19,269



HealthCare Global Enterprises Limited  
CIN : L15200KA1998PLC023489  
Regd. Office: HCG Tower, No. 8, P Kalanga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India  
Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India  
**STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2023**

**Notes:**

- 1 The statement of consolidated financial results ('the Statement') of HealthCare Global Enterprises Limited ('the Company'), its subsidiaries (collectively referred to as 'the Group') and its joint venture, for the quarter and year ended 31 March 2023 has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 25 May 2023. The Statement has been prepared in accordance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules 2015, as amended and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.

The consolidated figures for the year ended 31 March 2023 have been audited by the Statutory Auditors of the Company. The reports of the Statutory Auditors are unqualified. The consolidated figures for the quarters ended 31 March 2023 and 31 March 2022 are the balancing figures between audited figures in respect of the full financial years and the published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which were subjected to limited review by the Statutory Auditors of the Company.

- 2 During the quarter ended 30 June 2022, the Group revised the estimated useful life for certain category of its Property, Plant and Equipment with effect from 1 April 2022 based on its technical evaluation. The effect of this revision on depreciation expense of such assets is as mentioned below:

Particulars	Rs. in lakhs		
	Quarter ended 31 March 2023	Preceding quarter ended 31 December 2022	Year ended 31 March 2023
Depreciation charge on such assets is lower and profit before tax is higher by	139	139	566

- 3 Exceptional items:

There are no exceptional items in the current quarter and year ended 31 March 2023. Exceptional items for the previous year are as explained below:

a) The Company had been engaged in construction of greenfield project at leased premises in Gurugram ("project") since 2017. While the project was initially scheduled to be operational as of 2020, it was delayed due to changes in management's plan on account of operational priorities followed by the outbreak of COVID-19 pandemic. During the budgeting process in the quarter ended 31 December 2021, the Management decided to focus on increasing marketing activities and driving operational efficiencies and further invest in the upgrading and consolidating the existing footprint. As a result, the management decided not to pursue the project. The Company then had about two years of non-cancellable lease of the said premise. Accordingly, the Company recognized impairment of capital work-in progress, right-of use assets and security deposit aggregating to Rs. 4.725 Lakhs during the quarter ended 31 December 2021, after considering minimum lease payable and other committed costs of the project.

b) The Group invested Rs. 3,300 Lakhs in the equity shares of Suchirayu Health Care Solutions Limited (Suchirayu) on 18 November 2021 through primary funding, which resulted in increase in the Group's stake in Suchirayu from 17.7% to 78.6%. Suchirayu became subsidiary of the Group with effect from 18 November 2021, considering the Group's voting rights and its majority representation in the Board of Directors which gives it the current ability to unilaterally direct relevant activities of Suchirayu. During the quarter ended 31 December 2021, the Group remeasured its previously held interest in Suchirayu at fair value on the date of acquisition of additional stake and recognised the resultant gain of Rs. 174 Lakhs, net as an exceptional item in accordance with the applicable Indian Accounting Standard. With the acquisition of this business, the earlier medical services and the other related arrangements were cancelled.

c) During the quarter ended 30 September 2021, the Company sold its investment in Strand Life Sciences Private Limited ('Strand') for a total consideration of Rs. 15,778 lakhs, resulting in a gain of Rs. 14,194 lakhs (net of expenses / other provisions). The Company also entered into Business Transfer Agreement with Strand for acquisition of the diagnostic business and the division providing clinical research site management services for a total consideration of Rs. 8,080 Lakhs. With the acquisition of these businesses, the earlier outsourced Hospital Lab Management services were cancelled. The Company incurred Rs. 55 Lakhs towards legal and professional fees in respect of this acquisition during the year ended 31 March 2022.

d) During the quarter ended 30 September 2021, the Group refinanced its certain borrowings from banks and financial institutions. On account of this, the Group incurred one time expenses of Rs. 750 lakhs, towards foreclosure charges and accelerated amortization of loan processing fees related to earlier borrowings, which has been disclosed under Exceptional Items.

e) As on 30 September 2021, the Group paid CDC Group PLC (CDC) Rs. 411 lakhs towards its put option exercise in accordance with the shareholders agreement. On account of this settlement, Healthcare Global (Africa) Pvt Ltd (HCG Africa) became 100% subsidiary of the Group with effect from 30 September 2021. The Group remeasured its previously held equity interest in HCG Africa at its fair valuation on acquisition of the additional stake and recognized the resultant gain of Rs. 673 lakhs as an exceptional item in accordance with the applicable Indian Accounting Standard.

- 4 The Company plans to exercise the option permitted under section 115BAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019 with effect from the financial year 2023-24. Accordingly, the Company has recognised deferred taxes based on the rates applicable for the year when these deferred taxes are expected to be realized/settled. The impact of this change is recognised in the Consolidated Statement of Profit and Loss over the financial year 2022-23 based on the effective tax rate. The proportionate impact of this change is as mentioned below:

Particulars	Rs. in lakhs		
	Quarter ended 31 March 2023	Preceding quarter ended 31 December 2022	Year ended 31 March 2023
Deferred tax expense is lower by and profit after taxes is higher by	90	116	404

- 5 During the year ended 31 March 2023, 310,000 equity share options (year ended 31 March 2022 : 3,305,000 equity share options) having a face value of Rs. 10 each have been granted to the eligible employees of the Group under the Employee Stock Option Scheme (ESOP Scheme) at an exercise price of Rs. 130 per share respectively. Further, 104,070 equity shares (year ended 31 March 2022 : 149,240 equity shares) are allotted during the year pursuant to exercise of equity share options.

- 6 The Group has a single operating segment of 'setting up and managing hospitals and medical diagnostic services'.

Chicago, 25 May 2023

  
For and on behalf of the Board of Directors  
Dr. B. S. Ajaikumar  
Executive Chairman

